Top

Published in:

01-03-2017 | Original Article

Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson’s disease

Authors: Burcu Gökçe Çokal, Mustafa Yurtdaş, Selda Keskin Güler, Hafize Nalan Güneş, Ceyla Ataç Uçar, Bilal Aytaç, Zahide Esra Durak, Tahir Kurtuluş Yoldaş, İlker Durak, Hikmet Can Çubukçu

Published in: Neurological Sciences | Issue 3/2017

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). Oxidative stress has been hypothesized to play a major role in the development of PD in various studies. This study assessed to investigate oxidative and anti-oxidative status in PD patients. We evaluated oxidant/antioxidant status by measuring serum malondialdehyde (MDA) levels, xanthine oxidase (XO) activities, and activities of antioxidant enzymes, namely, glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD). The study included 29 patients with PD and 32 healthy subjects as controls. Comparison of oxidative parameters in the patient and control groups revealed significantly higher GSH-Px and XO activities in the patient group. Serum MDA and SOD activities in PD patients were not significantly different from the controls. MDA was negatively correlated with duration of the PD and positively with age of onset. There was a negative correlation between SOD and Hoehn and Yahr (H&Y) stage. According to these results, we suggest that oxidative stress may contribute to the development of PD.

Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912CrossRefPubMed

Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson’s disease. Front Neuroanat 8(9):91

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinic–pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184CrossRefPubMedPubMedCentral

Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRefPubMed

Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent Developments in Parkinson’s Disease, 2nd edn. Macmillan Health Care Information, Florham Park, pp 153–164

Dahle LK, Hill EG, Holman RT (1962) The thiobarbituric acid reaction and the autoxidations of polyunsaturated fatty acid methyl esters. Arch Biochem Biophys 98:53–261CrossRef

Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70(1):158–169PubMed

Durak I, Canbolat O, Kavutcu M, Ozturk HS, Yurtarslani Z (1996) Activities of total, cytoplasmic, and mitochondrial superoxide dismutase enzymes in sera and pleural fluids from patients with lung cancer. J Clin Lab Anal 10(1):17–20CrossRefPubMed

Hashimato S (1974) A new spectrophotometric assay method of xanthine oxidase in crude tissue homogenate. Anal Biochem 62(2):426–435CrossRef

10.

Neurologic Diseases in the Elderly Research Group, de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurology 54(11 Suppl 5):S21–S23

11.

Garrido M, Tereshchenko Y, Zhevtsova Z, Taschenberger G, Bahr M, Kugler S (2011) Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons. Acta Neuropathol 121:475–485CrossRefPubMed

12.

Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT (2011) The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson’s disease. Neuroscience 198:221–231CrossRefPubMedPubMedCentral

13.

Ghezzi P, Jaquet V, Marcucci F, Schmidt HH (2016) The oxidative stress theory of disease: levels of evidence and epistemological aspects. Br J Pharmacol. doi:10.1111/bph.13544 PubMed

14.

Halliwell B (2012) Free radicals and antioxidants: updating a personal view. Nutr Rev 70:257–265CrossRefPubMed

15.

Margis R, Dunand C, Teixeira FK, Margis-Pinheiro M (2008) Glutathione peroxidase family–an evolutionary overview. FEBS J 275(15):3959–3970CrossRefPubMed

16.

Niedernhofer LJ, Daniels JS, Rouzer CA, Greene RE, Marnett LJ (2003) Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J Biol Chem 278(33):31426–31433CrossRefPubMed

17.

Kostić DA, Dimitrijević DS, Stojanavić GS, Palić IR, Dordević AS, Ickovski D (2015) Xanthine oxidase: isolation, assays of activity, and inhibition. J Chem. doi:10.1155/2015/294858

18.

Kilinç A, Yalçin AS, Yalçin D, Taga Y, Emerk K (1988) Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson’s disease. Neurosci Lett 87:307–310CrossRefPubMed

19.

Abraham S, Soundararajan CC, Vivekanandhan S, Behari M (2005) Erythrocyte antioxidant enzymes in Parkinson’s disease. Indian J Med Res 121:111PubMed

20.

Poirier J, Barbeau A (1987) Erythrocyte antioxidant activity in human patients with Parkinson disease. Neurosci Lett 75:345–348CrossRefPubMed

21.

Kalra J, Rajput AH, Mantha SV, Prasad K (1992) Serum antioxidant enzyme activity in Parkinson’s disease. Mol Cell Biochem 110(2):165–168CrossRefPubMed

22.

Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993) Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience 52:1–6CrossRefPubMed

23.

Ye ZW, Zhang J, Townsend DM, Tew KD (2015) Oxidative stress, redox regulation and diseases of cellular differentiation. Biochim Biophys Acta 1850 8:1607–1621CrossRef

24.

Obata T, Kubota S, Yamanaka Y (2001) Allopurinol supresses para-nonylphenol and 1-methyl-4-phenylpyridinium ion (MPP+ induced hydroxyl radical generation in rat striatum. Neurosci Lett 306(1–2):9–12CrossRefPubMed

25.

Sudha K, Rao AV, Rao S, Rao A (2003) Free radical toxicity and antioxidants in Parkinson’s disease. Neurol India 51(1):60–62PubMed

26.

Baillet A, Chanteperdrix V, Trocmé C, Casez P, Garrel C, Besson G (2010) The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson’s disease. Neurochem Res 35(10):1530–1537CrossRefPubMed

27.

Sharma A, Kaur P, Kumar B, Prabhakar S, Gill KD (2008) Plasma lipid peroxidation and antioxidant status of Parkinson’s disease patients in the Indian population. Parkinsonism Relat Disord 14(1):52–57CrossRefPubMed

28.

Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Petersen RC, Kokmen E (1995) No evidence for systemic oxidant stress in Parkinson’s or Alzheimer’s disease. Mov Disord 10(5):566–573CrossRefPubMed

29.

Bostantjopoulou S, Kyriazis G, Katsarou Z, Kiosseoglou G, Kazis A, Mentenopoulos G (1997) Superoxide dismutase activity in early and advanced Parkinson’s disease. Funct Neurol 12(2):63–68PubMed

30.

de Farias CC, Maes M, Bonifácio KL, Bortolasci CC, de Souza Nogueira A, Brinholi FF, Matsumoto AK, do Nascimento MA, de Melo LB, Nixdorf SL, Lavado EL, Moreira EG, Barbosa DS (2016) Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson’s disease and its progression: disease and staging biomarkers and new drug targets. Neurosci Lett 617:66–71CrossRefPubMed

31.

Sanyal J, Bandyopadhyay SK, Banerjee TK, Mukherjee SC, Chakraborty DP, Ray BC, Rao VR (2009) Plasma levels of lipid peroxides in patients with Parkinson’s disease. Eur Rev Med Pharmacol Sci 13(2):129–132PubMed

32.

Chen CM, Liu JL, Wu YR, Chen YC, Cheng HS, Cheng ML, Chiu DT (2009) Increased oxidative damage in peripheral blood correlates with severity of Parkinson’s disease. Neurobiol Dis 33(3):429–435CrossRefPubMed

33.

Dotan Y, Lichtenberg D, Pinchuk I (2004) Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res 43:200–227CrossRefPubMed

34.

Colamartino M, Santoro M, Duranti G, Sabatini S, Ceci R, Testa A, Padua L, Cozzi R (2015) Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson’s disease. Neurotox Res 27(2):106–117CrossRefPubMed

35.

Alberio T, Pippione AC, Comi C, Olgiati S, Cecconi D, Zibetti M, Lopiano L, Fasano M (2012) Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson’s disease. IUBMB Life 64(10):846–852CrossRefPubMed

Title: Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson’s disease
Authors: Burcu Gökçe Çokal
Mustafa Yurtdaş
Selda Keskin Güler
Hafize Nalan Güneş
Ceyla Ataç Uçar
Bilal Aytaç
Zahide Esra Durak
Tahir Kurtuluş Yoldaş
İlker Durak
Hikmet Can Çubukçu
Publication date: 01-03-2017
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 3/2017
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-016-2782-8

2024 ASCO Annual Meeting

Springer Medicine

Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson’s disease

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

The role of deep breathing on stress

Risk factors for unprovoked epileptic seizures in multiple sclerosis: a systematic review and meta-analysis

Thoracic outlet syndrome: wide literature for few cases. Status of the art

Human herpes virus 6 brainstem encephalitis in a patient with primary macroglobulinemia

Steroid-responsive hyperammonemic encephalopathy as first manifestation of multiple myeloma

A wearable proprioceptive stabilizer for rehabilitation of limb and gait ataxia in hereditary cerebellar ataxias: a pilot open-labeled study